277 related articles for article (PubMed ID: 8608877)
1. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
2. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.
Landi B; Anh TN; Cortot A; Soule JC; Rene E; Gendre JP; Bories P; See A; Metman EH; Florent C
Gastroenterology; 1992 May; 102(5):1647-53. PubMed ID: 1568574
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Lerebours E; Bussel A; Modigliani R; Bastit D; Florent C; Rabian C; René E; Soulé JC
Gastroenterology; 1994 Aug; 107(2):357-61. PubMed ID: 8039612
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
9. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
10. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
[TBL] [Abstract][Full Text] [Related]
11. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB
Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
14. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
Gross V; Andus T; Ecker KW; Raedler A; Loeschke K; Plauth M; Rasenack J; Weber A; Gierend M; Ewe K; Schölmerich J
Gut; 1998 Apr; 42(4):493-6. PubMed ID: 9616309
[TBL] [Abstract][Full Text] [Related]
15. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
[TBL] [Abstract][Full Text] [Related]
16. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
17. A comparison of budesonide and mesalamine for active Crohn's disease.
Lowry PW; Sandborn WJ
Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
[No Abstract] [Full Text] [Related]
18. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
19. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
